PMID- 33224195
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1687-8337 (Print)
IS  - 1687-8345 (Electronic)
IS  - 1687-8337 (Linking)
VI  - 2020
DP  - 2020
TI  - Utilizing Technology-Enabled Intervention to Improve Blood Glucose 
      Self-Management Outcome in Type 2 Diabetic Patients Initiated on Insulin Therapy: 
      A Retrospective Real-World Study.
PG  - 7249782
LID - 10.1155/2020/7249782 [doi]
LID - 7249782
AB  - BACKGROUND: The aim of this study was to assess the benefits of a mobile-enabled 
      app through Lilly Connected Care Program (LCCP) in achieving blood glucose 
      control and adhering to self-monitoring of blood glucose in patients with type 2 
      diabetes mellitus (T2DM). METHODS: This retrospective study included T2DM 
      patients who were initiated on insulin therapy (mostly premixed insulin) after 
      failure to respond to oral antidiabetic drugs. Patients were provided with 
      glucometers enabled with synchronous data transmission to healthcare providers 
      and family members. The primary objective was to assess the benefits of LCCP 
      based on changes in fasting blood glucose (FBG) and postprandial glucose (PPG) 
      levels from baseline to 12 weeks. Paired t-test was used to assess the change in 
      blood glucose (BG) from baseline to week 12. RESULTS: In total, 14,085 T2DM 
      patients were recruited. Compared with baseline, significant reductions in FBG 
      and PPG were evident at week 12 (FBG: -0.39 mmol/L; PPG: -0.79 mmol/L; both P < 
      0.001). Furthermore, at week 12, the proportion of patients attaining a target 
      glucose level of FBG <7.0 mmol/L and PPG <10.0 mmol/L was 25.37% and 59.68%, 
      respectively, with a statistically significant increase compared with that at 
      baseline (6.74% and 45.59%, respectively, both P < 0.001). The frequent 
      monitoring of patients could gain a higher target achievement of FBG (28.1% vs 
      24.2%) and PPG (64.4% vs 55.1%) than the occasional monitoring patients. 
      Additionally, the incidence of hypoglycemia gradually decreased and was 
      significantly lower than the baseline level. CONCLUSIONS: In T2DM patients with 
      poor glycemic control, the application of mobile enabled intervention (LCCP) 
      along with insulin significantly reduced the hypoglycemia while improving 
      glycemic control during period of naive initiating insulin therapy. Additionally, 
      the high frequency of BG self-monitoring was associated with better glycemic 
      control.
CI  - Copyright (c) 2020 Jian Lin et al.
FAU - Lin, Jian
AU  - Lin J
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, and 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha 410011, Hunan, China.
FAU - Li, Xia
AU  - Li X
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, and 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha 410011, Hunan, China.
FAU - Jiang, Shan
AU  - Jiang S
AD  - Lilly (Shanghai) Management Co., Ltd, No. 288 Shimen No. 1 Road, Jingan District, 
      Shanghai 200041, China.
FAU - Ma, Xiao
AU  - Ma X
AD  - Lilly Suzhou Pharmaceutical Co., Ltd, No. 288 Shimen No. 1 Road, Jingan District, 
      Shanghai 200041, China.
FAU - Yang, Yuxin
AU  - Yang Y
AD  - Lilly Suzhou Pharmaceutical Co., Ltd, No. 288 Shimen No. 1 Road, Jingan District, 
      Shanghai 200041, China.
FAU - Zhou, Zhiguang
AU  - Zhou Z
AUID- ORCID: 0000-0002-0374-1838
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, and 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha 410011, Hunan, China.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC7671790
COIS- S. J., X. M., and Y. X. Y. report being employees of Eli Lilly and Company. The 
      other authors have no conflicts of interest to declare.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
PMCR- 2020/11/10
CRDT- 2020/11/23 05:38
PHST- 2020/06/15 00:00 [received]
PHST- 2020/09/29 00:00 [revised]
PHST- 2020/10/24 00:00 [accepted]
PHST- 2020/11/23 05:38 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
PHST- 2020/11/10 00:00 [pmc-release]
AID - 10.1155/2020/7249782 [doi]
PST - epublish
SO  - Int J Endocrinol. 2020 Nov 10;2020:7249782. doi: 10.1155/2020/7249782. 
      eCollection 2020.